Carcinogenesis, Vol. 23, No. 1, 107-114,
January 2002
© 2002 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Indomethacin induces differential expression of ß-catenin, 
-catenin and T-cell factor target genes in human colorectal cancer cells
1 Molecular Medicine Unit, University of Leeds, St James's University Hospital, Leeds LS9 7TF, UK and
2 Department of Medicine and
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA
Indomethacin-induced G1 arrest and apoptosis of human colorectal cancer (CRC) cells is associated with a dose-dependent decrease in ß-catenin protein levels. ß-catenin plays a pivotal role in the WNT signalling pathway and its expression is frequently dysregulated at early stages of colorectal carcinogenesis. The objective of this study was to investigate the effect of indomethacin on catenin expression and downstream WNT signalling events in human CRC cells. ß-catenin, 
-catenin and T-cell facter (TCF) target gene (cyclin D1, c-MYC and PPAR
) expression was studied following indomethacin treatment of SW480 and HCT116 cells. Cyclin D1 was used as a model TCF target gene for analysis of ß-catenin–TCF-4 DNA binding and trans-activation. Indomethacin treatment was associated with a specific decrease in ß-catenin (but not -catenin) expression. Resulting TCF target gene expression was gene specific (cyclin D1, decreased; c-MYC, increased; PPAR, no significant change). Cyclin D1 promoter analysis revealed that indomethacin disrupted formation of a ß-catenin–TCF-4–DNA complex. Indomethacin-induced G1 arrest and apoptosis is associated with specific ß-catenin down-regulation in human CRC cells in vitro. Differential expression of TCF target genes following indomethacin treatment implies complex effects on multiple genes which play an important role in colorectal carcinogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Tuynman, L. Vermeulen, E. M. Boon, K. Kemper, A. H. Zwinderman, M. P. Peppelenbosch, and D. J. Richel Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer Cancer Res., February 15, 2008; 68(4): 1213 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Calviello, F. Resci, S. Serini, E. Piccioni, A. Toesca, A. Boninsegna, G. Monego, F. O. Ranelletti, and P. Palozza Docosahexaenoic acid induces proteasome-dependent degradation of {beta}-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2 Carcinogenesis, June 1, 2007; 28(6): 1202 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, H. B. Cottam, M. Corr, and D. A. Carson Repression of {beta}-catenin function in malignant cells by nonsteroidal antiinflammatory drugs PNAS, December 20, 2005; 102(51): 18567 - 18571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Koornstra, F. E.M. Rijcken, C. N.A.M. Oldenhuis, N. Zwart, T. van der Sluis, H. Hollema, E. G.E. deVries, J. J. Keller, J. A. Offerhaus, F. M. Giardiello, et al. Sulindac Inhibits {beta}-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis Patients Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1608 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Bottone Jr., Y. Moon, J. S. Kim, B. Alston-Mills, M. Ishibashi, and T. E. Eling The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3) Mol. Cancer Ther., May 1, 2005; 4(5): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Yu, P. J. Moos, P. Cassidy, M. Wade, and F. A. Fitzpatrick Conditional Expression of 15-Lipoxygenase-1 Inhibits the Selenoenzyme Thioredoxin Reductase: MODULATION OF SELENOPROTEINS BY LIPOXYGENASE ENZYMES J. Biol. Chem., July 2, 2004; 279(27): 28028 - 28035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Rice, J. Kelloff, H. Sullivan, L. J. Driggers, K. S. Beard, S. Kuwada, G. Piazza, and D. J. Ahnen Sulindac metabolites induce caspase- and proteasome-dependent degradation of {beta}-catenin protein in human colon cancer cells Mol. Cancer Ther., September 1, 2003; 2(9): 885 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Bottone Jr., J. M. Martinez, J. B. Collins, C. A. Afshari, and T. E. Eling Gene Modulation by the Cyclooxygenase Inhibitor, Sulindac Sulfide, in Human Colorectal Carcinoma Cells: POSSIBLE LINK TO APOPTOSIS J. Biol. Chem., July 3, 2003; 278(28): 25790 - 25801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hawcroft, S. H. Gardner, and M. A. Hull Activation of Peroxisome Proliferator-Activated Receptor gamma Does Not Explain the Antiproliferative Activity of the Nonsteroidal Anti-Inflammatory Drug Indomethacin on Human Colorectal Cancer Cells J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Orner, W.-M. Dashwood, C. A. Blum, G. D. Diaz, Q. Li, and R. H. Dashwood Suppression of tumorigenesis in the Apcmin mouse: down-regulation of {beta}-catenin signaling by a combination of tea plus sulindac Carcinogenesis, February 1, 2003; 24(2): 263 - 267. [Abstract] [Full Text] [PDF]
|
|